智通财经APP获悉，易方达生物医药ETF(03186)涨近8%，截至发稿，涨7.7%，报15.8港元，成交额264.21万港元。
消息面上，因首个“mRNA个性化癌症疫苗”三期试验成功，隔夜疫苗巨头Moderna股价飙涨177%，引爆生物医药板块，纳斯达克生物科技指数大涨6.4%，创下六年来最大涨幅；今早港股多只相关概念股亦大涨超50%。据悉，这是首个在三期证明疗效的个性化新抗原疗法，也是首个mRNA癌症疗法的三期阳性读出，更是对“治疗性癌症疫苗能否走出概念”给出了硬证据。
公开资料显示，易方达生物医药ETF跟踪Solactive生物医药精选指数，精选港美上市生物医药公司，一站覆盖美股管线深度与中国成长红利。适合在肿瘤免疫/mRNA平台验证窗口，纪律化配置港美创新药β。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.